Thyrocare Technologies Limited's Board of Directors, in a meeting held on May 7, 2026, recommended a final dividend of ₹7.00 per equity share for the financial year 2025-26. This is in addition to the interim dividend of ₹7.00 per equity share already paid, bringing the total dividend for FY26 to ₹9.33 per share, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The Board also approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as the Statutory Auditors for a five-year term, commencing from the conclusion of the 26th AGM in 2026 until the 31st AGM in 2031, pending shareholder approval. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for the financial year 2026-27. In key personnel changes, Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for a further five years from May 4, 2027, to May 3, 2032, subject to shareholder approval. The Board also appointed Mr. Uday Patel Kadam and Mr. Gaurav Verma as Additional Directors (Non-Executive, Non-Independent) effective May 8, 2026. Concurrently, the Board noted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah as Non-Executive, Non-Independent Directors, both effective May 7, 2026, due to other commitments. Furthermore, the company approved an investment of up to ₹5.50 crore in the equity shares of its wholly-owned subsidiary, Think Health Diagnostics Private Limited, to support its operations and capital expenditure. The Memorandum of Association (MOA) of the company is also set to be altered to align with the Companies Act, 2013, and broaden its scope in the healthcare and diagnostics ecosystem.
